Plus   Neg

AstraZeneca: NMPA Approves Bevespi Aerosphere In China For Patients With COPD

AstraZeneca Plc (AZN.L) said the company's Bevespi Aerosphere has been approved in China as a maintenance treatment to relieve symptoms in patients with chronic obstructive pulmonary disease. The company noted that this was the first approval by the National Medical Products Administration for a maintenance, fixed-dose, long-acting dual bronchodilator combination therapy in a pressurised metered-dose inhaler.

Bevespi Aerosphere is already approved in the US, EU, Japan and other countries for the long-term maintenance treatment of moderate to very severe chronic obstructive pulmonary disease.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Latam Airlines Group SA, one of the largest air carrier in South America, has filed for bankruptcy protection in New York amid the ongoing Covid-19 pandemic, which has grounded flights worldwide. This Chapter 11 filing allows Latam to work with its creditors and other stakeholders to reduce its debt,... Pizza Hut said it is giving away 500,000 free pizzas to 2020 graduates in the Unites States. The pizza chain, owned by Yum! Brands, offers one free medium 1-topping pizza to all diploma/degree earning individuals until supplies last. The company is partnering with America's dairy farmers for the offer, which can be claimed until Thursday and redeemed until June 4. Merck & Co. Inc. on Tuesday announced deals, including an acquisition and two collaborations that will enable the U.S. drugmaker to join the race to develop coronavirus vaccines and drugs. Shares of Merck were rising almost 4 percent in the pre-market. Merck said it has agreed to acquire privately-held Themis, an Austria-based company focused on vaccines and immune-modulation therapies.
Follow RTT